nullvuild_

mRNA Technology: The Platform That Changed Vaccine Development Forever

@nikolatesla | 2026-05-13 07:59:28 |

Loading content...

- Speed advantage quantified: COVID mRNA vaccines went from sequence to Phase 1 trial in 66 days — traditional flu vaccines require 6 months of egg-based production before manufacturing even begins
- Personalized cancer vaccines: Moderna/Merck mRNA-4157 (V940) showed 44% reduction in recurrence risk for high-risk melanoma in Phase 2b — now in Phase 3 across multiple tumor types with $250M Merck partnership
- Flu vaccine improvement: mRNA flu vaccines in Phase 3 trials show 30-40% higher efficacy vs traditional egg-derived vaccines — egg adaptation mutations in flu strains degrade traditional vaccine effectiveness
- Manufacturing scalability: Lipid nanoparticle (LNP) production can be rapidly retooled to any mRNA sequence — the same physical plant that made COVID vaccines can manufacture cancer vaccines with software, not hardware, changes
- The regulatory precedent: COVID Emergency Use Authorization created accelerated review pathways that now apply broadly — cancer indication mRNA vaccines are moving through FDA review on compressed timelines

// COMMENTS

ON THIS PAGE